ACHV vs. MYGN, VSTM, EBS, LXRX, XOMA, CBIO, VNDA, CDXS, IRWD, and SGMO
Should you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Myriad Genetics (MYGN), Verastem (VSTM), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), XOMA Royalty (XOMA), Crescent Biopharma (CBIO), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), Ironwood Pharmaceuticals (IRWD), and Sangamo Therapeutics (SGMO). These companies are all part of the "biotechnology" industry.
Achieve Life Sciences vs. Its Competitors
Myriad Genetics (NASDAQ:MYGN) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.
99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 2.1% of Myriad Genetics shares are owned by company insiders. Comparatively, 3.0% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Myriad Genetics had 2 more articles in the media than Achieve Life Sciences. MarketBeat recorded 8 mentions for Myriad Genetics and 6 mentions for Achieve Life Sciences. Myriad Genetics' average media sentiment score of 1.08 beat Achieve Life Sciences' score of 0.50 indicating that Myriad Genetics is being referred to more favorably in the media.
Myriad Genetics currently has a consensus price target of $12.45, suggesting a potential upside of 82.73%. Achieve Life Sciences has a consensus price target of $14.67, suggesting a potential upside of 367.99%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than Myriad Genetics.
Achieve Life Sciences has lower revenue, but higher earnings than Myriad Genetics. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.
Myriad Genetics has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.
Achieve Life Sciences has a net margin of 0.00% compared to Myriad Genetics' net margin of -47.45%. Myriad Genetics' return on equity of -5.17% beat Achieve Life Sciences' return on equity.
Summary
Myriad Genetics beats Achieve Life Sciences on 9 of the 16 factors compared between the two stocks.
Get Achieve Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achieve Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ACHV) was last updated on 9/10/2025 by MarketBeat.com Staff
Free ACHV Stock Alerts